

Appln No.: 09/937,192
Amendment Dated: December 27, 2004
Reply to Office Action of June 25, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (canceled)

3. (currently amended) A chemical compound comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind leading to degradation in proteasomes of a subset of proteins requiring hsp90 for conformational maturation, said binding moieties being connected to one another by a linker, wherein the first and second hsp-binding moieties each retain the ability in the chemical compound to bind to the pocket of hsp90 and lead to degradation in proteasomes of a subset of proteins requiring hsp90 for conformational maturation.

4. (currently amended) The chemical compound of claim 3, wherein at least one of the hsp-binding moieties is geldanamycin, and the linker is connected to the 17-carbon of the geldanamycin.

5. (canceled)

6. (previously presented) The chemical compound of claim 4, wherein the linker has a length of 4 to 7 carbon atoms.

7-11. (canceled)

12. (currently amended) A method for destruction of cells expressing a HER-family tyrosine kinase, comprising administering to the cells a chemical compound comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind leading to degradation in proteasomes of a subset of proteins requiring hsp90 for conformational maturation, said binding moieties being connected to one another by a linker, wherein the first and second hsp-binding moieties each retain the ability in the chemical compound to bind to the pocket of hsp90 and lead to degradation in proteasomes of a subset of proteins requiring hsp90 for conformational maturation.

13. (currently amended) A method for treating cancer in a patient suffering from cancer, comprising administering to the patient a therapeutic composition comprising a chemical compound comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind leading to degradation in proteasomes of a subset of

Appln No.: 09/937,192

Amendment Dated: December 27, 2004

Reply to Office Action of June 25, 2004

proteins requiring hsp90 for conformational maturation, said binding moieties being connected to one another by a linker, wherein the first and second hsp-binding moieties each retain the ability in the chemical compound to bind to the pocket of hsp90 and lead to degradation in proteasomes of a subset of proteins requiring hsp90 for conformational maturation.

14. (original) The method of claim 13, wherein the cancer is an HER-positive cancer.

15. (currently amended) The method according to claim 13, wherein at least one of the hsp-binding moieties is geldanamycin, and the linker is connected to the 17-carbon of the geldanamycin.

16. (original) The method according to claim 15, wherein the linker has a length of 4 to 7 carbon atoms.

17. (original) The method according to claim 16, wherein the linker has a length of 4 carbon atoms.

18-20 (canceled).

21. (currently amended) The method according to claim 14, wherein at least one of the hsp-binding moieties is geldanamycin, and the linker is connected to the 17-carbon of the geldanamycin.

22. (original) The method according to claim 21, wherein the linker has a length of 4 to 7 carbon atoms.

23. (original) The method according to claim 22, wherein the linker has a length of 4 carbon atoms.

24-26 (canceled)

27. (currently amended) The method according to claim 12, wherein at least one of the hsp-binding moieties is geldanamycin, and the linker is connected to the 17-carbon of the geldanamycin.

28. (original) The method according to claim 27, wherein the linker has a length of 4 to 7 carbon atoms.

29. (original) The method according to claim 28, wherein the linker has a length of 4 carbon atoms.

Appln No.: 09/937,192

Amendment Dated: December 27, 2004

Reply to Office Action of June 25, 2004

30. (previously presented) The method of claim 13, wherein the cancer is one in which the cancer cells overexpress a HER-family kinase.

31. (previously presented) The method of claim 13, wherein the cancer is breast cancer.

32. (previously presented) The method of claim 13, wherein the cancer is ovarian cancer.

33. (previously presented) The method of claim 13, wherein the cancer is pancreatic cancer.

34. (previously presented) The method of claim 13, wherein the cancer is gastric cancer.